An emerging biotech company’s transition from focusing on R&D into a fully-integrated commercial organization is an exciting journey full of important decisions. In this webinar, a panel of seasoned executives who have grappled firsthand with these questions shared some of their experiences and lessons learned. Panelists touched on a range of topics, including
- The overall journey in evolving from an R&D-focused company to a commercial organization
- The most important things for a company to get right early on, including key components for shaping the market, the product, and the company
- Best practices and common pitfalls, especially related to things that decision-makers in emerging companies most often underestimate
Panelists:
- Jessica Meng, Chief Commercial Officer, Delfi Diagnostics
- Richa Poddar, Chief Commercial Officer, Agios
- Tim Varacek, Chief Commercial Officer, Allakos
- Moderator: Joe Magliocco, Principal, Blue Matter
